Tulane National Primate Research Center

该申请要求为杜兰国家灵长类动物研究中心（TNPRC）提供五年的资金 从2008年5月1日到2013年4月30日。资金将用于支持行政管理， 业务、兽医资源、科学研究资源以及教育和培训使命 中心额外资金用于支持试点研究项目和与蜂群健康有关的研究资源 项目也被要求。 近三十年来，TNPRC研究计划的主要重点一直是传染病。 这将继续下去。此外，一个重要的基因治疗计划与该中心密切相关， 杜兰大学的基因治疗在过去五年中得到了发展。主要的供资领域 传染病方案目前有艾滋病、莱姆病和生物防御相关制剂;还有 正在开发的领域，如结核病。这些是多学科的研究， TNPRC的多个部门和中心外的合作者。这些研究涵盖了从 传播和发病机制的研究，以开发疫苗策略和化疗治疗。的 基因治疗计划提供了一个重要的链接到大学的其余部分，允许新的方法， 治疗多种类型的疾病，并赋予我们的研究计划额外的多样性。 自上次提交TNPRC基本赠款以来，这一时期一直是显著增长的时期， 中心的改善。赞助资金总额大幅增加，个人，研究者 在上次提交基本赠款时，启动赠款现已超过赠款总额。我们目前在 我们的设施开始大规模扩建，以支持不断增长的研究计划。总 目前项目的建设预算超过5000万美元，将增加约80，000平方英尺， 设施。扩建工程由众多NIH建筑奖（C 06，UC 6）和私人基金资助。的 特别值得一提的是区域生物安全实验室。这是一个BSL-3设施，将重点放在生物防御和 新出现的感染，以支持NIH生物防御研究议程。 基于过去五年的进展，我们对未来非常乐观。优势， 我们可以利用包括重大资助的翻新和扩建项目，一个研究重点（传染性 疾病和基因治疗），符合NIH和国家优先事项，教师任命，强大的， 多样化的研究资源，有才华和敬业的工作人员，良好的互动和合作， 地区大学，并与我们的主办机构和州和联邦立法者的杰出关系。

This application requests funding for the Tulane National Primate Research Center (TNPRC) for the fiveyear period beginning May 1, 2008 through April 30, 2013. Funds will be used to support the administration, operations, veterinary resources, scientific research resources and education and training mission of the Center. Additional funds to support pilot research projects and colony-health-related research resource projects are also requested. For nearly three decades the main focus of the TNPRC research program has been infectious disease. This will continue. In addition, a significant program in gene therapy that is tightly linked to the Center for Gene Therapy at Tulane has developed over the last five years. The major areas of funding for the infectious disease program are currently AIDS, Lyme disease and biodefense-related agents; there are also areas under development, such as tuberculosis. These are multidisciplinary studies involving investigators in multiple Divisions at the TNPRC and collaborators outside the Center. The studies cover the spectrum from transmission and pathogenesis to development of vaccine strategies and chemotherapeutic treatments. The gene therapy program provides an important link to the rest of the University, allows for novel approaches to the treatment of many types of disease and imparts additional diversity to our research program. The period since the last submission of the TNPRC base grant has been a time of significant growth and improvement at the Center. Total sponsored funding has increased dramatically and individual, investigator initiated awards now exceed total awards at the time of the last base grant submission. We are currently at the beginning of a major expansion of our facilities in support of the growing research program. The total construction budget for current projects is in excess of $50M and will add approximately 80,000sf to the facility. The expansion is funded by numerous NIH construction awards (C06, UC6) and private funds. Of particular note is the Regional Biosafety Laboratory. This is a BSL-3 facility that will focus on biodefense and emerging infections in support of the NIH biodefense research agenda. Based on the progress in the last five years we are very optimistic about the future. Strengths on which we can capitalize include significant funded renovation and expansion projects, a research focus (infectious diseases and gene therapy) that matches NIH and national priorities, faculty appointments, strong and diverse research resources, a talented and dedicated staff, excellent interactions and collaborations with area universities and an outstanding relationship with our host institution and state and federal legislators.